Voices
Karamvir Yadav: Liquid Biopsy Is Reshaping First-Line mCRPC Decision-Making
Karamvir Yadav/X

Karamvir Yadav: Liquid Biopsy Is Reshaping First-Line mCRPC Decision-Making

Karamvir Yadav, Medical Oncologist in Jaipur, India, shared posts on X about a recent article by Andrew Armstrong et al, adding:

“One step more towards precision oncology

Key PROpel biomarker message:

  • 85% HRRm concordance
  • 94% BRCAm concordance
  • ctDNA success rate 92%
  • Minimal false negatives

Liquid biopsy is reshaping first-line mCRPC decision-making.”

Title: Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial

Authors: Andrew Armstrong, Fred Saad, Mototsugu Oya, Neal Shore, Giuseppe Procopio, Cagatay Arslan, Niven Mehra, Emma Brown, Jae Young Joung, Mikio Sugimoto, Mustafa Özgüroğlu, Craig Gedye, Oliver Sartor, Christian Poehlein, Ping Qiu, Yu-Zhen Liu, Xiaodun Li, Elizabeth Harrington, David McGuinness, Jinyu Kang, Alan Barnicle, Noel Clarke

Read the Full Article on Journal of Clinical Oncology

More posts featuring Karamvir Yadav.

Alan Barnicle Andrew Armstrong Cagatay Arslan cancer Christian Poehlein Craig Gedye David McGuinness Elizabeth Harrington Emma Brown Fred Saad Giuseppe Procopio Jae Young Joung Jinyu Kang Karamvir Yadav Mikio Sugimoto Mototsugu Oya Mustafa Özgüroğlu Neal Shore Niven Mehra Noel Clarke Oliver Sartor OncoDaily Oncology Ping Qiu Xiaodun Li Yu-Zhen Liu